重组人醌氧化还原酶2，Quinone Oxidoreductase 2 (NQO2) human；recombinant, expressed in E. coli, ≥90% (SDS-PAGE), ≥100 units/mg protein

Quinone oxidoreductase 2 has been used in a study to investigate whether recent advances in limiting paraquat′s toxicity makes it safer for use as an herbicide. Quinone oxidoreductase 2 has also been used in a study to investigate the NQO2-mediated toxicity of the chemotherapeutic drug CB1954.

The product from Sigma has been used to identify novel inhibitors of the enzyme NQO2.[1] It has also been used to investigate the effect of afobazole on quinone reductase 2 activity.[2]

 

Modulation of NQO2 activity can have effects on the levels and functions of the tumour suppressor, p53. Deletion of NQO2 can alter intra-cellular signalling via the NF-κB pathway.[1]

Unique human oxidoreductase that uses Dihydronicotinamide riboside (NRH) as a cosubstrate, not NAD(P)H. Activates anticancer prodrugs. Putative melatonin receptor.

 

One unit will catalyze the oxidation of one micromole of 1-methyl-1,4-dihydronicotinamide to 1-methylnicotinamide per minute in the presence of menadione at pH 7.4 at 37 °C.

 

contains 10% PBS buffer salts